ACTB

Across TCGA pan-cancer cohorts, ACTB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTB data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACTB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTB expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where ACTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.254	0.709	.005	14	view →
CCRCC	DFS	Median	All	0.514	0.908	.006	11	view →
PDAC	OS	Median	All	0.680	0.464	.010	10	view →
LSCC	OS	Tertile	II,III,IV	0.740	0.957	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTB–LUAD (DFS)

Open the LUAD breakdown →